Insider buying last 90 days
No open-market insider purchases were filed for PHVS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PHVS insider filing, plotted on the chart in Gekko.Open PHVS in Gekko
NASDAQ: PHVS
Pharvaris (PHVS) Stock Analysis & Forecast
Oct 12 close
$30.89−0.21 (−0.7%)
Gekko Brief
AI summaryOct 12 closePharvaris moves this week on clinical and analyst news around its hereditary angioedema program. Phase 3 RAPIDe-3 data published in the Lancet showed deucrictibant immediate-release capsule delivering statistically significant faster symptom relief in HAE attacks, and a related real-world study pointed to patient and physician preference for daily oral treatment over injectables. Following the data, H.C. Wainwright reiterated a Buy rating with a $60 price target, citing the HAE therapy's potential and an overlooked opportunity in acquired angioedema.
Shares close at $30.89, down 0.7%, sitting between the 50-day average of $34.74 and the 200-day average of $30.63. The stock is off 18.8% over one month and 10.3% over three months, though still up 10.8% over six months and 35.2% over the past year. The GekkoIndex reads 68.1, placing PHVS in the Accumulation zone, down 2.9 over five days. Price sits 20.1% below Gekko Fair Value of $38.67.
The next earnings date falls on 11 November 2026, 29 days out and beyond a typical 20-trading-day hold; the prior report on 11 August showed a loss of $0.81 per share against a $0.74 estimate, with a 4.6% reaction. Analyst coverage stands at 11 buy and 1 hold among 12 firms, with a consensus target of $57.38, implying 85.8% upside. Seasonality over the next 20 trading days has averaged -3.2% across 5 years, positive in 1 of them. One trailblazer holder is recorded, with no other smart-money or options activity noted in the respective 90-day and 30-day windows.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Pharvaris price vs fair value
Close $30.89200-day averageGekko Fair Value $38.67
Pharvaris quick facts
- Market cap
- $2.16B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.06
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- -2.46
- Volume
- 646,015 avg 749,209
- 1-year return
- +35.2%
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±9.1%
- 50-day average
- $34.74
- 200-day average
- $30.63
- Next earnings
- Nov 11
- Shares outstanding
- 70.21M
Pharvaris swing-trade checklist
Pharvaris scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $30.89 sits between the 50-day ($34.74) and 200-day ($30.63) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
68.1, Accumulation
Reading 68.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
20.1% below
Price is 20.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Nov 11, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−3.2% on average
From this point in the calendar, the next 20 trading days averaged −3.2% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Pharvaris stock chart and price history
Pharvaris closed at $30.89 on Oct 12, 2026, +35.2% over the past year, inside a 52-week range of $20.65 to $43.25.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −18.8%
- 3 months
- −10.3%
- 6 months
- +10.8%
- 1 year
- +35.2%
The full PHVS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PHVS in Gekko
Follow Pharvaris through every session
Put PHVS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PHVS in GekkoFree for 7 days. No credit card required.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company working on treatments for rare conditions linked to bradykinin activity, with a particular focus on angioedema. Its efforts center on hereditary angioedema and acquired angioedema caused by C1-inhibitor deficiency, two conditions that fall under this bradykinin-mediated category. The company is best known for deucrictibant, a small molecule designed to block the bradykinin B2 receptor and address attacks tied to these diseases.
Deucrictibant is being studied in multiple phase 3 trials, covering both the treatment of acute attacks and prophylactic use to prevent them in hereditary angioedema patients. Pharvaris is also developing the compound in two different forms, an extended-release tablet and an immediate-release capsule, to support these different treatment approaches.
The company was incorporated in 2015 and is based in Zug, Switzerland. Its shares trade on the NASDAQ under the ticker PHVS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- pharvaris.com
Pharvaris GekkoIndex: the smart money zone
Pharvaris’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.1, in the Accumulation zone, down 2.9 points over five sessions.
68.1Accumulation
Down 2.9 points over five sessions, from the Buying zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 22 | +9.7% | +13.6% | ||
| Accumulation (current zone) | 218 | +0.5% | +1.1% | ||
| Neutral | 414 | 0.0% | +1.2% | ||
| Distribution | 25 | −2.9% | −10.4% | ||
| Selling | 3 | Too few readings yet | |||
Average PHVS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the PHVS price, zone by zone.Track PHVS in Gekko
Is Pharvaris stock overvalued? Gekko Fair Value
Pharvaris trades 20.1% below Gekko Fair Value of $38.67, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Pharvaris shares are worth, recalculated every trading day.
$38.67
Gekko Fair Value, Oct 10, 2026
20.1% Undervalued
At the end of Aug 2026 the price was 21.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PHVS in Gekko
Pharvaris insider and Congress trading
No open-market insider purchases were filed for Pharvaris, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PHVS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PHVS, plotted on the chart in Gekko.Open PHVS in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds PHVS.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Pharvaris earnings: next date and track record
Pharvaris reports on Nov 11, 2026 (30 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 11, 2026
30 days away
- EPS estimate
- −$0.82
- Revenue estimate
- $2.34M
2 of 8reports beat the EPS estimate
±3.3%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$0.81 est −$0.74 | — | +4.6% |
| Apr 2, 2026 | −$0.71 est −$0.62 | — | −3.7% |
| Dec 31, 2025 | −$0.71 est −$0.62 | — | +0.9% |
| Nov 12, 2025 | −$0.60 est −$0.67 | — | +0.6% |
| Aug 12, 2025 | −$0.83 est −$0.77 | — | +2.8% |
| May 13, 2025 | −$0.85 est −$0.83 | — | −4.4% |
| Mar 31, 2025 | −$0.64 est −$0.73 | — | −6.1% |
| Nov 13, 2024 | −$0.77 est −$0.60 | — | +3.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Pharvaris stock forecast and analyst price targets
Analysts’ average 12-month price target for Pharvaris is $57.38, +85.8% from the last close, from 12 firms rating the stock in the last 90 days.
$57.38consensus 12-month target, +85.8% from the last close
Now $30.89Avg $57.38
Low $44High $79
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Morgan Stanley | $62 | +100.7% |
| Oct 6 | H.C. Wainwright | $60 | +94.2% |
| Oct 5 | Morgan Stanley | $62 | +100.7% |
| Sep 28 | Morgan Stanley | $62 | +100.7% |
| Sep 21 | Morgan Stanley | $62 | +100.7% |
+1.1%average 20-day move after past Accumulation readings
−3.2%average move over the next 20 trading days in the last 5 years
±4.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Pharvaris seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Pharvaris averaged −3.2% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.7% | 2 of 5 |
| Next 10 trading days | +3.7% | 2 of 5 |
| Next 15 trading days | +2.5% | 3 of 5 |
| Next 20 trading days | −3.2% | 1 of 5 |
| Next 30 trading days | −13.0% | 2 of 5 |
For scale, PHVS’s typical 20-trading-day move in either direction is about 9.1%.
Pharvaris market cap and key statistics
Pharvaris’s market cap is $2.16B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $2.16B
- EPS, TTM
- −$3.06
- Gekko Fair Value
- $38.67
Trading
- Volume
- 646,015
- Avg volume, 20 days
- 749,209
- 52-week high
- $43.25
- 52-week low
- $20.65
- Shares outstanding
- 70.21M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -70.5%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -2.46
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±9.1%
Pharvaris stock news this week
Coverage of Pharvaris this week reads positive: 3 positive, 1 neutral and 0 negative headlines.
- Pharvaris N.V. (PHVS) stock price, news, quote and historyYahoo Finance Singapore, Oct 10
- Pharvaris HAE drug shows faster symptom relief in Lancet studyInvesting.com, Oct 9
- Pharvaris stock reiterated Buy at H.C. Wainwright on HAE therapy potentialInvesting.com Nigeria, Oct 7
- Will Real World HAE Study Change Pharvaris Stock NarrativeSimply Wall Street, Oct 6
Pharvaris peers
Pharvaris’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Pharvaris stock FAQ
What is Pharvaris’s market cap?
Pharvaris’s market cap is $2.16B at the Oct 12, 2026 close of $30.89, with 70.21M shares outstanding.
What is the Pharvaris stock forecast?
The consensus analyst 12-month price target for Pharvaris is $57.38, +85.8% from the last close. Of the 12 firms that rated the stock in the last 90 days, 11 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Pharvaris stock overvalued or undervalued?
On Gekko’s estimate Pharvaris is undervalued: the Oct 12, 2026 close of $30.89 is 20.1% below Gekko Fair Value of $38.67. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Pharvaris report earnings next?
Pharvaris is expected to report on Nov 11, 2026 (30 days away). Analysts expect earnings of −$0.82 per share on revenue of $2.34M. Pharvaris beat the earnings estimate in 2 of its last 8 reports, moving 3.3% on average across the report.
What is Pharvaris’s 52-week high and low?
Pharvaris’s 52-week high is $43.25 and its 52-week low is $20.65; it closed at $30.89 on Oct 12, 2026, +35.2% over the past year.
Is Pharvaris stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Pharvaris the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.